Ligand Pharma (LGND) Pops Higher Ahead of FDA Committee Vote for Carfilzomib (ONXX)
Tweet Send to a FriendGet Alerts LGND Hot Sheet
Up)
Trade LGND Now!
Ligand Pharmaceuticals (Nasdaq: LGND) shares are up 10 percent as the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is currently discussing carfilzomib's application as a treatment for multiple myeloma.
Ligand is a partner with Onyx Pharma (Nasdaq: ONXX) on the drug. The spike could be a positive indication for the outcome.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Ligand is a partner with Onyx Pharma (Nasdaq: ONXX) on the drug. The spike could be a positive indication for the outcome.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Can AMD (AMD) Shake Off the Goldman Downgrade?
- Will Erickson Air-Crane (EAC) Stock Crash and Burn?
- Tableau Software (DATA) IPO indicated $37-$40 after pricing at $31
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Momentum Movers
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
